Lonza's dual-payload ADC platform advances to clinic with Antharis gastrointestinal cancer deal
Lonza (SIX: LONN) has granted San Diego-based Antharis Therapeutics, Inc. an exclusive, target-specific license to its proprietary dual-payload ADC platform for the development of antibody-drug conjugates targeting gastrointestinal cancers. Antharis's lead program is described as about to enter the clinic, making this one of the more advanced applications of Lonza's dual-payload technology to reach clinical-stage commitment. Financial terms were not disclosed.
Under the agreement, Lonza is eligible to receive upfront, milestone, and royalty payments on net sales. Antharis retains full responsibility for research, clinical development, manufacturing, and commercialization of the resulting ADCs, while Lonza manufactures components related to its proprietary payload and linker technologies.
Lonza's site-specific ADC technology is built on the Synaffix platform — acquired in June 2023 — which combines GlycoConnect antibody conjugation, HydraSpace polar spacer, and toxSYN linker-payload technologies. Together, these enable controlled, homogeneous drug-to-antibody ratios without requiring antibody re-engineering, a distinction that has made the platform attractive to a broad range of partners. The dual-payload extension, the layer specifically licensed to Antharis, allows a single ADC molecule to carry two mechanistically distinct cytotoxic payloads via sequential bioorthogonal click chemistry, described by Lonza as designed to overcome tumor heterogeneity and acquired resistance to single-payload agents.
The specific GI cancer target and the identity of the payloads have not been disclosed. The lead program is described as preclinical to early clinical, with Antharis contributing proprietary antibody engineering and target biology expertise to complement Lonza's conjugation and manufacturing capabilities.
Industry and transaction context
The Antharis deal is the latest in a sequence of Lonza platform licensing transactions that has accelerated noticeably in 2026. Just eleven days before the Antharis announcement, Lonza signed a multi-target license agreement with Stipple Bio to advance precision oncology ADC therapies using the same GlycoConnect-based platform. In January 2026, Lonza's Synaffix unit entered a multi-target agreement with Sidewinder Therapeutics for next-generation bispecific ADCs, with Lonza eligible to receive upfront, milestone, and royalty payments — the same economic structure applied here. In September 2025, Synaffix licensed its dual-payload technology to South Korea-based Qurient Therapeutics, combining Synaffix's exatecan-based payload with Qurient's CDK7 inhibitor. The pattern reflects a deliberate out-licensing strategy: Lonza retains manufacturing rights for its proprietary components while distributing development risk across multiple partners operating in distinct target spaces.
What distinguishes the Antharis deal from earlier Synaffix agreements is the explicit dual-payload focus and the near-clinical stage of the lead program. Most prior Synaffix licenses — including the Qurient and Stipple Bio deals — were earlier-stage platform access arrangements without a named clinical candidate. Antharis's stated readiness to enter the clinic positions this as a more immediate revenue opportunity for Lonza's milestone stream, though the absence of any disclosed upfront figure makes it difficult to benchmark against comparable transactions.
The concentration of Lonza platform deals in Q1 and Q2 2026 — Stipple Bio, Sidewinder, Qurient, and now Antharis — suggests the dual-payload extension is drawing increased interest as the field moves toward multi-warhead ADC strategies. Whether Lonza's target-specific exclusivity model will constrain the platform's reach across GI indications, where multiple companies are pursuing overlapping targets, remains a structural question as the partner pipeline expands.
This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/
Spot something wrong? Report an issue with this article
Summary
Lonza (SIX: LONN) has granted San Diego-based Antharis Therapeutics, Inc. an exclusive, target-specific license to its proprietary dual-payload ADC platform...